-transparent.png){kind=logo}
We studied, clinicopathologically, 34 cases of adenosquamous carcinoma (ASC) treated in our institution over the last 30 years. Its incidence was 2.3% of all primary lung cancers. Following findings were characteristics to this type of lung cancer, male dominant, old age, heavy smoker, comparatively large diameter, peripheral location, and normal level of tumor makers. The 5-year survival rates were 35.0% for ASC, 38.1% for squamous cell carcinoma (SCC), and 50.2% for adenocarcinoma (AC). The component of SCC was predominant or equal to that of AC in 27 (79.4%) ASC cases. The degree of cell differentiation was moderate and both SCC and AC components showed the same degree of cell differentiation in most cases. Lymph node metastasis was seen in 15 (48.4%) cases.
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
February 2013,
Pathology international,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
December 2011,
Pathology international,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
January 2024,
American journal of translational research,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
June 2015,
Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
February 1986,
Gan no rinsho. Japan journal of cancer clinics,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
October 2022,
Japanese journal of clinical oncology,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
January 2018,
OncoTargets and therapy,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
November 1997,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
January 2018,
Oncotarget,
T Mukaida, and
M Aoe, and
M Yamashita, and
H Date, and
K Hara, and
A Andoh, and
Y Shimizu
December 2022,
Japanese journal of clinical oncology,
